Efficacy and safety of avelumab treatment in patients with metastatic Merkel cell carcinoma: experience from a global expanded access program

BACKGROUND: Avelumab, a human anti–programmed death-ligand 1 immunoglobulin G1 monoclonal antibody, showed favorable efficacy and safety in patients with metastatic Merkel cell carcinoma (mMCC) in the phase II JAVELIN Merkel 200 trial, leading to approval in multiple countries. We describe real-worl...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Julkaisussa:J Immunother Cancer
Päätekijät: Walker, John W, Lebbé, Celeste, Grignani, Giovanni, Nathan, Paul, Dirix, Luc, Fenig, Eyal, Ascierto, Paolo Antonio, Sandhu, Shahneen, Munhoz, Rodrigo, Benincasa, Elena, Flaskett, Sarah, Reed, Josh, Engelsberg, Arne, Hariharan, Subramanian, Kasturi, Vijay
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: BMJ Publishing Group 2020
Aiheet:
Short Report
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC7252959/
https://ncbi.nlm.nih.gov/pubmed/32269140
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/jitc-2019-000313
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia